Yıl: 2019 Cilt: 9 Sayı: 3 Sayfa Aralığı: 228 - 231 Metin Dili: İngilizce DOI: 10.33808/clinexphealthsci.599707 İndeks Tarihi: 12-11-2020

Investigation of Potential Anticarcinogenic Effects of Corilagin in Lung Cancer Cells

Öz:
Objective: Lung cancer (LC) is the most extensive reason of cancer associated deaths in men and women in the world. LC categorizes into two maingroups due to their molecular clinicopathological features and therapeutic responses. Non-small cell lung cancer (NSCLC) is the main subgroup thatconsists of nearly 85% of all lung cancer types. Corilagin, a biologically active ellagitannin, could be extracted from Phyllanthus species which areknown as Chinese medicinal plant. It has been recently shown that Corilagin could exert anti-inflammatuar and antioxidative effects in differentexperimental cancer models. However, the molecular effects of Corilagin in NSCLC remain unclear.Methods: In this study, the antiproliferative and apoptotic effects of Corilagin were identified by WST-1 cell proliferation test, caspase-3 andmitochondrial membrane potential (MMP).Results: We found that Corilagin significiantly suppressed the proliferation of NSCLC cells. Furthermore, we also showed that Corilagin couldcontribute apoptosis by inducing activity of caspase-3 molecule and loss of MMP.Conclusion: Taken together, our study first showed that Corilagin could be a new treatment method for NSCLC after verifying its effects with in vivoand clinical studies.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • [1] Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011;12:175–180.
  • [2] Travis WD. Classification of lung cancer. Semin Roentgenol 2011;46:178–186.
  • [3] Wu Q, Chen YF, Fu J., You QH, Wang SH, Huang X, Feng XJ, Zhang SH. Short hairpin RNA-mediated down-regulation of CENPA attenuates the aggressive phenotype of lung adenocarcinoma cells. Cell Oncol 2014;37:399–407.
  • [4] Koren A., Motaln H., Cufer T. Lung cancer stem cells: a biological and clinical perspective. Cell Oncol 2013;36: 265–275.
  • [5] Peled N, Wynes MW, Ikeda N, Ohira T, Yoshida K, Qian J, Illoze M, Brenner R, Kato Y, Mascaux C, Hirsch FR. Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. Cell Oncol 2013;36:277–288.
  • [6] Maier A, Peille AL, Vuaroqueaux V, Lahn M. Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts. Cell Oncol 2015; 38: 131-144.
  • [7] Ulivi P, Silvestrini R. Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer. Cell Oncol 2013;36:439–448.
  • [8] Giaccone G. Twenty-five years of treating advanced NSCLC: what have we achieved? Ann Oncol 2004;4:81–83.
  • [9] Neal JW, Sequist LV. Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh. Curr Treat Options in Oncol 2010;11:36–44.
  • [10] Sangha R, Lara PN, Mack PC, Gandara DR. Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier. Curr Opin Oncol 2009;21:116–123.
  • [11] Mateen S, Raina K, Agarwal R. Chemopreventive and anticancer efficacy of silibinin against growth and progression of lung cancer. Nutr Cancer J 2013;65:3–11.
  • [12] Hau DK, Gambari R, Wong RS, Yuen MC, Cheng GY, Tong CS, Zhu GY, Leung AK, Lai PB, Lau FY, Chan AK, Wong WY, Kok SH, Cheng CH, Kan CW, Chan AS, Chui CH, Tang JC, Fong DW. Phyllanthus urinaria extract attenuates acetamionophen induced hepatotoxicity: involvement of cytochrome P450 CYP2E1. Phytomedicine 2009;16:751– 760.
  • [13] Shen ZQ, Dong ZJ, Peng H, Liu JK. Modulation of PAI-1 and tPA activity and thrombolytic effects of corilagin. Planta Med 2003;69:1109–1112.
  • [14] Sudjaroen Y, Hull WE, Erben G, Wuertele GM, Changbumrung S, Ulrich CM, Owen RW. Isolation and characterization of ellagitannins as the major polyphenolic components of Longan (Dimocarpus longan Lour) seeds. Phytochemistry 2012;77:226–237.
  • [15] Okabe S, Suganuma M, Imayoshi Y, Taniguchi S, Yoshida T, Fujiki H. New TNF-a releasing inhibitors, geraniin and corilagin, in leaves of acer nikoense, megusurino-ki. Biological and Pharmaceutical Bulletin 2001;24,10:1145–1148.
  • [16] Duan W, Yu Y, Zhang L. Antiatherogenic effects of phyllanthus emblica associated with corilagin and its analogue. Yakugaku Zasshi 2005;125:587–591.
  • [17] Cheng JT, Lin TC, Hsu FL. Antihypertensive effect of corilagin in the rat. Can. J Physiol Pharmacol 1995;73:1425–1429.
  • [18] Duan WG, Shen ZQ, Yan M, Yun Y, Zhang LY. Corilagin, a promis¬ing natural product to treat cardiovascular diseases. In: Singh VK, Mishra SK, Govil JN, editors. Phytopharmacology and Therapeutic Values II. Houston: Studium Press; 2008:163– 172.
  • [19] Kinoshita S, Inoue Y, Nakama S, Ichiba T, Aniya Y. Antioxidant and hepatoprotective actions of medicinal herb, Terminalia catappa L. from Okinawa Island and its tannin corilagin. Phytomedicine 2007;14, 11: 755–762.
  • [20] Hau DK, Zhu GY, Leung AK, Wong RS, Cheng GY, Lai PB, Tong SW, Lau FY, Chan KW, Wong WY, Lam KH, Cheng CH, Cheung F, Chui CH, Gambari R, Fong DW. In vivo anti-tumour activity of corilagin on Hep3B hepatocellular carcinoma. Phytomedicine 2010;15, 18(1):11-15.
  • [21] Gambari R, Hau DK, Wong WY, Chui CH. Sensitization of Hep3B hepatoma cells to cisplatin and doxorubicin by corilagin. Phytother Res 2014;28(5):781-783.
  • [22] Ming Y, Zheng Z, Chen L, Zheng G, Liu S, Yu Y, Tong Q. Corilagin inhibits hepatocellular carcinoma cell proliferation by inducing G2/M phase arrest. Cell Biol Int 2013;37(10):1046-1054.
  • [23] Jia L, Jin H, Zhou J, Chen L, Lu Y, Ming Y, Yu Y. A potential antitumor herbal medicine, Corilagin, inhibits ovarian cancer cell growth through blocking the TGF-β signaling pathways. BMC Complement Altern Med 2013;15: 13:33.
  • [24] Muresan XM, Cervellati F, Sticozzi C, Belmonte G, Chui CH, Lampronti I, Borgatti M, Gambari R, Valacchi G. The loss of cellular junctions in epithelial lung cells induced by cigarette smoke is attenuated by corilagin. Oxid Med Cell Longev 2015;2015: 631-758.
  • [25] Wang Z, Guo QY, Zhang XJ, Li X, Li WT, Ma XT, Ma LJ. Corilagin attenuates aerosol bleomycin-induced experimental lung injury. Int J Mol Sci 2014;30:15(6):9762-9779.
APA Rencüzoğulları Ç, CINCIN Z, Bireller S, Baran Y, Cakmakoglu B (2019). Investigation of Potential Anticarcinogenic Effects of Corilagin in Lung Cancer Cells. , 228 - 231. 10.33808/clinexphealthsci.599707
Chicago Rencüzoğulları Çağla,CINCIN ZEYNEP BIRSU,Bireller Sinem,Baran Yusuf,Cakmakoglu Bedia Investigation of Potential Anticarcinogenic Effects of Corilagin in Lung Cancer Cells. (2019): 228 - 231. 10.33808/clinexphealthsci.599707
MLA Rencüzoğulları Çağla,CINCIN ZEYNEP BIRSU,Bireller Sinem,Baran Yusuf,Cakmakoglu Bedia Investigation of Potential Anticarcinogenic Effects of Corilagin in Lung Cancer Cells. , 2019, ss.228 - 231. 10.33808/clinexphealthsci.599707
AMA Rencüzoğulları Ç,CINCIN Z,Bireller S,Baran Y,Cakmakoglu B Investigation of Potential Anticarcinogenic Effects of Corilagin in Lung Cancer Cells. . 2019; 228 - 231. 10.33808/clinexphealthsci.599707
Vancouver Rencüzoğulları Ç,CINCIN Z,Bireller S,Baran Y,Cakmakoglu B Investigation of Potential Anticarcinogenic Effects of Corilagin in Lung Cancer Cells. . 2019; 228 - 231. 10.33808/clinexphealthsci.599707
IEEE Rencüzoğulları Ç,CINCIN Z,Bireller S,Baran Y,Cakmakoglu B "Investigation of Potential Anticarcinogenic Effects of Corilagin in Lung Cancer Cells." , ss.228 - 231, 2019. 10.33808/clinexphealthsci.599707
ISNAD Rencüzoğulları, Çağla vd. "Investigation of Potential Anticarcinogenic Effects of Corilagin in Lung Cancer Cells". (2019), 228-231. https://doi.org/10.33808/clinexphealthsci.599707
APA Rencüzoğulları Ç, CINCIN Z, Bireller S, Baran Y, Cakmakoglu B (2019). Investigation of Potential Anticarcinogenic Effects of Corilagin in Lung Cancer Cells. Clinical and Experimental Health Sciences, 9(3), 228 - 231. 10.33808/clinexphealthsci.599707
Chicago Rencüzoğulları Çağla,CINCIN ZEYNEP BIRSU,Bireller Sinem,Baran Yusuf,Cakmakoglu Bedia Investigation of Potential Anticarcinogenic Effects of Corilagin in Lung Cancer Cells. Clinical and Experimental Health Sciences 9, no.3 (2019): 228 - 231. 10.33808/clinexphealthsci.599707
MLA Rencüzoğulları Çağla,CINCIN ZEYNEP BIRSU,Bireller Sinem,Baran Yusuf,Cakmakoglu Bedia Investigation of Potential Anticarcinogenic Effects of Corilagin in Lung Cancer Cells. Clinical and Experimental Health Sciences, vol.9, no.3, 2019, ss.228 - 231. 10.33808/clinexphealthsci.599707
AMA Rencüzoğulları Ç,CINCIN Z,Bireller S,Baran Y,Cakmakoglu B Investigation of Potential Anticarcinogenic Effects of Corilagin in Lung Cancer Cells. Clinical and Experimental Health Sciences. 2019; 9(3): 228 - 231. 10.33808/clinexphealthsci.599707
Vancouver Rencüzoğulları Ç,CINCIN Z,Bireller S,Baran Y,Cakmakoglu B Investigation of Potential Anticarcinogenic Effects of Corilagin in Lung Cancer Cells. Clinical and Experimental Health Sciences. 2019; 9(3): 228 - 231. 10.33808/clinexphealthsci.599707
IEEE Rencüzoğulları Ç,CINCIN Z,Bireller S,Baran Y,Cakmakoglu B "Investigation of Potential Anticarcinogenic Effects of Corilagin in Lung Cancer Cells." Clinical and Experimental Health Sciences, 9, ss.228 - 231, 2019. 10.33808/clinexphealthsci.599707
ISNAD Rencüzoğulları, Çağla vd. "Investigation of Potential Anticarcinogenic Effects of Corilagin in Lung Cancer Cells". Clinical and Experimental Health Sciences 9/3 (2019), 228-231. https://doi.org/10.33808/clinexphealthsci.599707